Literature DB >> 17613807

Obesity, insulin resistance, and renal function.

Sarah F Knight1, John D Imig.   

Abstract

There is a growing body of evidence indicating that obesity and insulin resistance contribute to the progression of renal disease. A low-grade inflammatory response occurs in obesity and insulin resistance that causes an increase in macrophage infiltration into the adipose tissue and the kidney. The infiltration of macrophages gives rise to the production of an array of pro-inflammatory cytokines and downstream elements such as interleukin-6, NFkappaB, and cellular adhesion molecules. In addition, increased adiposity triggers the release of adipokines such as leptin that can cause vascular remodeling and disruption of renal function. Insulin resistance can alter the balance between endogenous vasoactive molecules such as nitric oxide and reactive oxygen species, resulting in altered renal endothelial function. Moreover, hyperinsulinemia has direct renal effects such as induced relaxation of the afferent arteriole, resulting in glomerular hyperfiltration and renal damage. High insulin levels also stimulate angiogenesis and mesangial cell proliferation, associated with the development of diabetic nephropathy. Current evidence indicates a direct link between increased adiposity and insulin resistance with renal vascular injury; however, further investigation into the renal microvascular effects of obesity and insulin resistance are required to better understand this disease process.

Entities:  

Mesh:

Year:  2007        PMID: 17613807     DOI: 10.1080/10739680701283018

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  21 in total

Review 1.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

2.  Activation of inflammasomes in podocyte injury of mice on the high fat diet: Effects of ASC gene deletion and silencing.

Authors:  Krishna M Boini; Min Xia; Justin M Abais; Guangbi Li; Ashley L Pitzer; Todd W B Gehr; Yang Zhang; Pin-Lan Li
Journal:  Biochim Biophys Acta       Date:  2014-02-05

3.  Secoisolariciresinol diglucoside in high-fat diet and streptozotocin-induced diabetic nephropathy in rats: a possible renoprotective effect.

Authors:  Iman O Sherif
Journal:  J Physiol Biochem       Date:  2014-10-15       Impact factor: 4.158

Review 4.  Role of the Renal Microcirculation in Progression of Chronic Kidney Injury in Obesity.

Authors:  Alejandro R Chade; John E Hall
Journal:  Am J Nephrol       Date:  2016-10-22       Impact factor: 3.754

5.  Obesity is not associated with contrast nephropathy.

Authors:  Navin Jaipaul; Rendell Manalo; Seyed-Ali Sadjadi; James McMillan
Journal:  Ther Clin Risk Manag       Date:  2010-05-25       Impact factor: 2.423

6.  The Common FTO Genetic Polymorphism rs9939609 is Associated with Increased BMI in Type 1 Diabetes but not with Diabetic Nephropathy.

Authors:  Harvest F Gu; Alexandra Alvarsson; Kerstin Brismar
Journal:  Biomark Insights       Date:  2010-04-27

Review 7.  Insulin and its role in chronic kidney disease.

Authors:  Robert H Mak
Journal:  Pediatr Nephrol       Date:  2007-10-11       Impact factor: 3.714

8.  Obesity and vascular dysfunction.

Authors:  Phoebe A Stapleton; Milinda E James; Adam G Goodwill; Jefferson C Frisbee
Journal:  Pathophysiology       Date:  2008-06-20

9.  Increased peripheral vascular disease risk progressively constrains perfusion adaptability in the skeletal muscle microcirculation.

Authors:  Jefferson C Frisbee; Joshua T Butcher; Stephanie J Frisbee; I Mark Olfert; Paul D Chantler; Lawrence E Tabone; Alexandre C d'Audiffret; Carl D Shrader; Adam G Goodwill; Phoebe A Stapleton; Steven D Brooks; Robert W Brock; Julian H Lombard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-12-23       Impact factor: 4.733

Review 10.  Eicosanoids and renal damage in cardiometabolic syndrome.

Authors:  John D Imig
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-02       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.